News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Siegfried (USA), Inc. and Jazz Pharmaceuticals, Inc. (JAZZ) Sign Supply Agreement


5/28/2010 10:13:28 AM

Pennsville, NJ, 12 May 2010 –Siegfried (USA) Inc is pleased to announce that on April 1, 2010, a Supply Agreement with Jazz Pharmaceuticals Inc. was executed. Siegfried has the right to supply at least 60% of Jazz Pharmaceutical’s worldwide requirements of sodium oxybate, the active pharmaceutical ingredient in Xyrem® (sodium oxybate) oral solution, pending DEA registration, quota approval and FDA approval as a manufacturer.

Siegfried will carry out all required process transfer and manufacturing at Siegfried (USA) Inc.’s FDA and DEA registered site in Pennsville, NJ. Commercial manufacture of sodium oxybate is expected to commence after Siegfried obtains the required DEA and FDA approvals and the manufacturing process is transferred from Jazz Pharmaceuticals’ current supplier.

Dr. Walter Kittl, Senior Vice President and General Manager of Siegfried (USA) Inc, states “Sodium oxybate provides an excellent fit with our expertise in the manufacturing of controlled substances and our proven capacity to perform exclusive synthesis. We are excited to work together with Jazz Pharmaceuticals to secure the supply chain of this important drug”.

Sodium oxybate is the sodium salt form of gamma-hydroxybutyrate, an endogenous neurotransmitter and metabolite of GABA. Sodium oxybate is the active ingredient in XYREM® (sodium oxybate) oral solution, approved by the FDA and marketed by Jazz Pharmaceuticals in the U.S. for the treatment of excessive daytime sleepiness and cataplexy (the sudden loss of muscle tone) in adult patients with narcolepsy.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES